Honorary SWEBAGS Members 2026: Professors Glenda Halliday & Maria Grazia Spillantini

SWEBAGS is proud to announce the nomination of our 2026 honorary members:

Professor Glenda Halliday and Professor Maria Grazia Spillantini.

Both professors have made exceptional and lasting contributions to our understanding of neurodegenerative diseases and basal ganglia–related disorders, shaping the way the field approaches both basic and clinical research. Their work has had a major impact on how we think about disease mechanisms, biomarkers, and treatment strategies, and has inspired generations of researchers and clinicians worldwide.

To celebrate their achievements, SWEBAGS will host a special honorary webinar with Professors Halliday and Spillantini on 27 February at 11:30 (Stockholm time), as part of our ongoing basal ganglia webinar series.

Honorary SWEBAGS Webinar 2026

Honorary SWEBAGS Members 2026: Professors Glenda Halliday & Maria Grazia Spillantini Read More »

Nominate an Honorary Member of SWEBAGS

The SWEBAGS Board invites nominations for honorary membership. Honorary membership recognizes individuals who have made exceptional contributions to the field of basal ganglia research or to the Society.

Nominations must be sent via email to the Board. Please include in your nomination:

  • The nominee’s name and contact details
  • A brief statement explaining why the individual should be considered for honorary membership

Nominations are reviewed by the Board. The Board selects candidates to be proposed for approval at the upcoming annual meeting. Please note that all nominations will be handled confidentially, and only elected honorary members will be announced on the website.

For questions, contact the SWEBAGS Board at [email protected]

We look forward to receiving your nominations!

Nominate an Honorary Member of SWEBAGS Read More »

Invitation: MDJ Symposium – Neurobiology of Parkinson’s Disease

SWEBAGS is pleased to highlight an upcoming satellite event of the 2025 SfN Neuroscience meeting – the Movement Disorders Journal (MDJ) Symposium: Neurobiology of Parkinson’s Disease, held in San Diego, CA, USA on November 14, 2025. This scientific gathering is organized by the editorial team of Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society. ​

The symposium offers a comprehensive exploration of the biological foundations of Parkinson’s disease (PD), including the genetics and cellular mechanisms underlying PD, novel translational approaches for managing dyskinesias, and updates on emerging experimental platforms for research and therapy.

To learn more about the symposium and to access the official website, please click on the image below, scan the provided QR code or follow the link: https://www.movementdisorders.org/Events/MDJ-Symposium.htm

Invitation: MDJ Symposium – Neurobiology of Parkinson’s Disease Read More »

SWEBAGS Conference 2025

Building on the successes of previous years, we are excited to once again open our digital doors for an online one-day conference on December 11th, 2025.

We’re excited to announce this year’s keynote speakers: Ana Munoz Manchado, Marcus Stephenson-Jones and Marco Pignatelli. The program will also feature selected talks and posters from submitted abstracts—presenters will have a unique opportunity to share their work with an engaged, international audience.

New for this year:


To further simplify participation, abstract submission will be managed via a Google Form this year. Registration and attendee information will still be handled directly through the SWEBAGS website using your SWEBAGS account. If you don’t have a free SWEBAGS account yet, register here. This will also give you access to our webinar archive with more than 50 webinars by leading researchers in our field.

Important dates:
Abstract submission deadline: October 24th 2025
Conference: December 11th, 2025

Why Participate?
* Share and gain knowledge through keynotes, intriguing presentations, and engaging discussions
* Present your findings to an international audience for feedback and recognition.
* Forge new connections and explore collaborations.
* Benefit from a repository of webinars and resources exclusive to members.

We hope to see you in December!

/SWEBAGS Organising Committee 2025

SWEBAGS Conference 2025 Read More »

EduBrains – Call for Proposals

EBRAINS Germany has launched a call for EduBrains, a training program for master’s and doctoral students in STEM interested in e-health technologies for brain research. The program is interdisciplinary, includes both online and on-site modules, and offers participants the chance to learn about the EBRAINS research infrastructure and connect with international experts.

Read more and apply by September 4, 2025:
https://foldercase.com/proext.php?pid=466

EduBrains – Call for Proposals Read More »

Open position as Assistant Professor and Group Leader at Lund University (Lund, Sweden) 

Area: Neurodegenerative disease research, with focus on disease mechanisms.

Faculty affiliation: Medical Faculty

5-years position with the opportunity for promotion to permanent employment as a senior lecturer.

  • The salary is covered by Lund University
  • Several forms of support will be provided by the strategic research area MultiPark (multidisciplinary research on neurogenerative diseases, https://www.multipark.lu.se)

How to apply

Applications are to be made electronically via Lund University’s applications portal by August 17, 2025:https://lu.varbi.com/en/what:job/jobID:831173/?where=36

Eligibility

  • Applicants should have obtained a doctoral degree within 7 years from the closing date for the applications (i.e., not earlier than 2018) . An earlier doctoral-degree date is acceptable if there are documents proving parental leave, military service, illness, or other significant circumstances that have prevented the candidate from working as a researcher after graduation.
  • The candidate should have several years of experience in biomedical-related research, having carried out a postdoctoral training in an international environment outside of Sweden.
  • Research in the field should have resulted in publications at a high scientific level.

For additional information you may contact Angela Cenci Nilsson, MultiPark Director , [email protected]

Open position as Assistant Professor and Group Leader at Lund University (Lund, Sweden)  Read More »

Postdoc opportunity in the Trudeau lab in Montreal to study dopamine neuron biology and vulnerability

Exploring the fundamental mechanisms of dopamine release and dopamine neuron
vulnerability
Supervisor: Dr. Louis-Eric Trudeau


A postdoc position is presently available in the laboratory of Dr. Louis-Eric Trudeau at the
University of Montreal to work on projects that focus on the fundamental mechanisms of
dopamine release and on the vulnerability of these neurons in Parkinson’s disease models.
The ideal applicant is someone who recently completed (or is very close to completing) a
Ph.D. in the field of neuroscience, has experience in the use of mouse models and
techniques such as fluorescence-based approaches, electrophysiology/electrochemistry
and the use of viral vectors. Accomplishments in the form of peer-reviewed publications is
also expected. The successful candidate will work on exploring the molecular mechanisms
that mediate different forms of dopamine release and the links between dopamine neuron
connectivity and their vulnerability in Parkinson’s disease models. The work with involve a
range of state-of-the-art techniques including mouse genetics, genetically encoded
neurotransmitter sensors, in vitro and in vivo models and a range of fluorescence imaging
approaches. Competitive salary support will be provided. The Université de Montréal is one
of the top research universities in Canada and the city of Montreal offers an ideal
combination of critical mass in the field of neuroscience and quality of life. The applicant is
also expected to apply the University of Montreal Center for Biomedical Innovation
postdoctoral fellowship competition (https://cibmontreal.ca/en/news/launch-of-the-2025-
postdoctoral-fellowship-competition/) (deadline May 27).


Contact: [email protected].
https://www.labotrudeau.org/
https://pubmed.ncbi.nlm.nih.gov/?term=Trudeau+LE&sort=date

Postdoc opportunity in the Trudeau lab in Montreal to study dopamine neuron biology and vulnerability Read More »

New Publication: Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa-Induced Dyskinesia

Authors: Abdolaziz Ronaghi, Tiberiu Loredan Stan, Sebastian A. Barrientos, Pär Halje, Azat Nasretdinov, Luciano Censoni, Sebastian Sulis Sato Evgenya Malinina, Joakim Tedroff, Nicholas Waters, Per Petersson

Abstract: Levodopa provides effective symptomatic treatment for Parkinson’s disease. However, nonmotor symptoms are often insufficiently relieved, and its long-term use is complicated by motor fluctuations and dyskinesia. To clarify mechanisms of levodopa-induced dyskinesia and pharmacological interventions aimed at reducing dyskinetic symptoms, we have here characterized the neurophysiological activity patterns in sensorimotor and cognitive-limbic circuits in dyskinetic rats, comparing the effects of amantadine, pimavanserin, and the novel prospective antidyskinetic and antipsychotic treatment mesdopetam. Parallel recordings of local field potentials from 11 cortical and subcortical regions revealed suppression of narrowband gamma oscillations (NBGs) in sensorimotor structures by amantadine and mesdopetam in conjunction with alleviation of dyskinetic signs. Concomitant gamma oscillations in cognitive-limbic circuits were not directly linked to dyskinesia and were not affected by antidyskinetic treatments to the same extent, although treatment-induced reductions in functional coupling were observed in both sensorimotor and cognitive-limbic circuits, in parallel. In a broad frequency spectrum (1-200 Hz), mesdopetam treatment displayed greater similarities to pimavanserin than to amantadine. These findings point to the reduction of NBGs as a valuable biomarker for the characterization of antidyskinetic treatment effects and provide systems-level mechanistic insights into the antidyskinetic efficacy of mesdopetam, with potential additional benefits for the treatment of Parkinson’s-related psychosis.

DOI: 10.1111/ejn.70032

New Publication: Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa-Induced Dyskinesia Read More »